In March 2025, the company introduced new designs for a immediate-to-buyer presenting of its Wegovy weight loss drug. The company established a whole new pharmacy, identified as NovoCare, which would charge prospects $499 each month for entry to the drug, fewer than half the cost of the drug by way of other pharmaceutical distribution networks.[53]